iBio Inc. [AMEX: IBIO] stock went on an upward path that rose over 0.58% on Friday, amounting to a one-week price decrease of less than -0.57%. The company report on November 6, 2020 that iBio to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Update on Monday, November 16,2020.
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced that it will report its fiscal 2021 first quarter financial results after market close on Monday, November 16, 2020. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
The live and archived webcast may be accessed on the Company’s website at www.ibioinc.com under “News and Events” in the Investors section. The live call can be accessed by dialing (833) 672-0651 (domestic) or (929) 517-0227 (international) and entering conference code: 2546666.
Over the last 12 months, IBIO stock rose by 967.90%. The average equity rating for IBIO stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $317.26 million, with 180.29 million shares outstanding and 179.68 million shares in the current float. Compared to the average trading volume of 18.91M shares, IBIO stock reached a trading volume of 4219732 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on iBio Inc. [IBIO]:
Alliance Global Partners have made an estimate for iBio Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 26, 2020.
The Average True Range (ATR) for iBio Inc. is set at 0.10, with the Price to Sales ratio for IBIO stock in the period of the last 12 months amounting to 198.29. The Price to Book ratio for the last quarter was 3.39, with the Price to Cash per share for the same quarter was set at 0.30.
IBIO Stock Performance Analysis:
iBio Inc. [IBIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.57. With this latest performance, IBIO shares dropped by -16.02% in over the last four-week period, additionally plugging by 54.46% over the last 6 months – not to mention a rise of 967.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBIO stock in for the last two-week period is set at 40.69, with the RSI for the last a single of trading hit 37.58, and the three-weeks RSI is set at 40.87 for iBio Inc. [IBIO]. The present Moving Average for the last 50 days of trading for this stock 2.0030, while it was recorded at 1.7020 for the last single week of trading, and 1.8183 for the last 200 days.
Insight into iBio Inc. Fundamentals:
iBio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.60 and a Current Ratio set at 11.80.
iBio Inc. [IBIO] Insider Position Details
There are presently around $20 million, or 9.50% of IBIO stock, in the hands of institutional investors. The top three institutional holders of IBIO stocks are: BLACKROCK INC. with ownership of 5,448,105, which is approximately 25.874% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 1,708,991 shares of the stock with an approximate value of $2.96 million in IBIO stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $1.22 million in IBIO stock with ownership of nearly 116.363% of the company’s market capitalization.
52 institutional holders increased their position in iBio Inc. [AMEX:IBIO] by around 5,074,746 shares. Additionally, 20 investors decreased positions by around 705,339 shares, while 7 investors held positions by with 5,634,934 shares. The mentioned changes placed institutional holdings at 11,415,019 shares, according to the latest SEC report filing. IBIO stock had 33 new institutional investments in for a total of 1,660,406 shares, while 16 institutional investors sold positions of 582,510 shares during the same period.